Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

Multiple Sclerosis

Amy - A person with MS; RMS diagnosis in 2018. Started OCREVUS in 2021 aged 24.

We’re committed to advancing the clinical understanding of underlying disease activity and progression for the millions of people living with multiple sclerosis (MS) worldwide.
Multiple sclerosis Product
OCREVUS (ocrelizumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
OCREVUS is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.¹

Challenge

MS is a progressive disease. While MS can present itself differently for each person, its underlying biology is similar for everyone. No matter what form of MS a person is diagnosed with, disease progression is present from the start.

MS is an immune-mediated disease of the central nervous system and the leading cause of non-traumatic disability in young adults, affecting people in the prime of their lives. Disease progression was once only associated with secondary progressive and primary progressive MS but is now recognised in relapsing remitting MS, even if a person is not experiencing relapses.

Focus

MS and disease progression can be a complicated topic to understand. As we gain a deeper understanding of disease progression and the different ways MS can present itself inside the body, we know that it’s a disease that can be managed and should be treated as early as possible.

Our ongoing research continues to advance our understanding of MS disease progression and what lies within the jungle of the brain.

There’s a symbiotic relationship between our understanding of MS and our tools for measuring it – better understanding leads to better tools, and better tools lead to a better understanding. We learn as we go, both in science and in the measurement of disease and its impact.

At Roche we’re committed to advancing on both fronts.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre 
by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. 


 
As OCREVUS is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

Reference:

1. OCREVUS® Summary of Product Characteristics (GB and NI).

You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.